Dynavax Technologies Corporation
12/29/2025 | Press release | Distributed by Public on 12/29/2025 06:34
(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of the persons filing statement) (Form SC14D9C)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Dynavax Technologies Corporation
(Name of Subject Company)
Dynavax Technologies Corporation
(Name of Person(s) Filing Statement)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title of Class of Securities)
268158201
(CUSIP Number of Class of Securities)
Ryan Spencer
Chief Executive Officer
Dynavax Technologies Corporation
2100 Powell Street, Suite 720
Emeryville, California 94608
(510) 848-5100
With copies to:
Barbara L. Borden
Bill Roegge
Steven M. Przesmicki
Cooley LLP
10265 Science Center Drive
San Diego, California 92121
(858) 550-6000
(Name, address, and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
| ☒ |
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Items 1.01, 7.01 and 9.01 of the Current Report on Form 8-K filed by Dynavax Technologies Corporation on December 29, 2025 (including all exhibits attached thereto) is incorporated herein by reference.
Dynavax Technologies Corporation published this content on December 29, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 29, 2025 at 12:34 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]